Rare Diseases

In the field of rare diseases, Ipsen takes a patient-focused approach to improving the lives of people affected by rare disorders and develops high-quality, innovative treatments that address unmet needs. Our goal is to support patients with drugs, services and solutions across the entire continuum of care, from diagnosis to treatment follow-up.

We have a social contract with society; that means society is counting on us to accelerate the access of drugs to meet patients in need.

David Meek, CEO

Our areas of expertise

Our rare diseases pipeline

Further developing our presence in rare diseases constitutes a natural path forward for Ipsen.  In the future, we will continue to expand in this area with high unmet need, leveraging expertise from development to commercialization to establish leadership positions and provide innovative treatments.

We will strengthen our pipeline and portfolio through targeted business development efforts, considering multiple factors in our assessment such as disease prevalence and severity, availability of treatments and the commercial and technological fit with Ipsen.

In particular, we will strengthen our portfolio with a particular emphasis on treatments for children.  We believe we need to provide our caregivers and our physicians with the ability to treat these patients with new options and the launch of new trials is crucial this.  This is why we believe the challenges are diminishing but the opportunities are growing.



By partnering with Ipsen, you will gain access to a like-minded global biopharmaceutical company with powerhouse development and commercialization teams. We are willing to take bold steps to translate your science and innovations into impactful products for patients in need.

Learn more

Partnerships with patients and healthcare providers

Ipsen’s support for acromegaly patients goes beyond treatments. The Acromunity.com website, launched in 2017 in conjunction with patients and healthcare professionals, offers a platform, that delivers content, tools and services to match their needs, from the time of first symptoms to years after diagnosis.

In the United States, Ipsen supports IPSEN CARES™ (Coverage, Access, Reimbursement and Education Support), a program that assists patients in overcoming obstacles to start or continue treatment with SOMATULINE® for gastroenteropancreatic NETs and acromegaly, as well as INCRELEX® and DYSPORT®.  The website includes advice on issues relating to access, distribution and financial concerns.

In Europe, the Group has set up INKEP (Ipsen Network of Knowledge Exchange Program) for small groups of physicians specializing in pediatric endocrinology. It combines scientific presentations, case discussions and interactive sit-in clinic visits.

Other initiatives in pediatric endocrinology include APPRI in France, a personalized training program for patients that helps increase their autonomy at home during treatment with the recombinant growth hormone NUTROPINAQ® and the NUTROPINAQ® injection pen, which improves treatment compliance.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019